Results Announced from Ph 2 SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in ovarian cancer cohort and the cervical cancer cohorts April 21, 2026
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Ph 2 Results March 10, 2026
Results from Ph 2 POC study of HLX43 in recurrent/metastatic cervical cancer published December 9, 2025
Hong Kong Department of Health approves TIVDAK (tisotumab vedotin-tftv) in Hong Kong for patients with recurrent or metastatic cervical cancer September 3, 2025
LIfT BioSciences granted €12M from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy August 5, 2025
First Patient Dosed with Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab July 1, 2025
Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical Cancer May 13, 2025
TIVDAK (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer April 2, 2025
SGO 2025: Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer March 26, 2025
Positive Topline Results for TIVDAK in the China Subpopulation of the Global Ph 3 innovaTV 301 Trial in Patients with Recurrent/Metastatic Cervical Cancer Announced January 21, 2025
FDA Grants Fast Track Designation to CRB-701 for the Treatment of R/R Metastatic Cervical Cancer December 10, 2024
KEYTRUDA + chemo approved in the EU for patients with primary advanced/recurrent endometrial carcinoma and + chemoRT for patients with Stage III-IVA locally advanced cervical cancer October 29, 2024
FAILED TRIAL: Ph 2 study of TG4001 + avelumab vs avelumab in patients with R/M HPV16-positive cervical and anogenital tumors did not meet the primary objective of PFS improvement October 15, 2024
First patient enrolled in Ph 1/2a clinical trial for Lenti-HPV07 against oropharyngeal and cervical cancers October 15, 2024
36-Month OS Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation Announced October 8, 2024
FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers October 8, 2024
Positive EU CHMP Opinions for KEYTRUDA Regimens as Treatment for Patients With cervical cancer and endometrial carcinoma September 24, 2024
Ph 2 trial of VB10.16 with or without Tecentriq initiated for the treatment of HPV16+ve, PD-L1+ve, recurrent or metastatic cervical cancer May 1, 2024
KEYTRUDA + CRT Significantly Improved OS Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer March 18, 2024
Tisotumab Vedotin MAA Validated by EMA for Treatment of Recurrent or Metastatic Cervical Cancer February 26, 2024
TIVDAK® Supplemental BLA Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer January 17, 2024
FDA Approves KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer January 17, 2024
